Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
This trial is active, not recruiting.
|Conditions||i cell disease, fucosidosis, globoid cell leukodystrophy, adrenoleukodystrophy, mannosidosis, niemann-pick disease, pulmonary complications, mucopolysaccharidosis i, mucopolysaccharidosis vi, metachromatic leukodystrophy, gaucher's disease, wolman disease|
|Sponsor||Fairview University Medical Center|
|Start date||August 1999|
|Trial size||10 participants|
|Trial identifier||NCT00005900, 199/15111, UMN-MT-1999-18, UMN-MT-9818|
OBJECTIVES: I. Evaluate bronchoalveolar lavage fluid and serum obtained from pediatric patients with storage disorders prior to allogeneic hematopoietic stem cell transplantation (HSCT) for the presence of proinflammatory cytokines and for the production of nitric oxide by alveolar macrophages to identify possible risk factors for pulmonary complications.
II. Investigate the underlying mechanism for the development of significant pulmonary complications in these patients during HSCT.
III. Evaluate bronchoalveolar lavage fluid and serum obtained from these same patients at the time a pulmonary complication develops post-HSCT, or at 60 days post-HSCT if there has been no pulmonary complications.
Male or female participants of any age.
- Diagnosis of an inborn error of metabolism eligible for allogeneic hematopoietic stem cell transplantation on protocol UMN-MT-1995-01
|Description||PROTOCOL OUTLINE: Patients undergo bronchoscopy with bronchoalveolar lavage (BAL) prior to allogeneic hematopoietic stem cell transplantation (HSCT). ELISA assays for cytokines are performed. Patients are followed post-HSCT for the development of transplant related pulmonary complications. A repeat bronchoscopy with BAL is performed at the time pulmonary complications develop or at day 60 post-HSCT if no complications develop. Cytokine assays are repeated.|
Call for more information